Clinical trial NCT01989507: Very Low-Nicotine Cigarettes in Smokers With SUD
Official title: Very Low-Nicotine Cigarettes in Smokers With SUD: Smoking, Substance Use Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Nicotine Dependence
Keywords: tobacco smoking
smoking cessation
nicotine dependence
tobacco use disorder
Lead sponsor: Brown University
Sponsor class: OTHER
First posted: 2013-11-21
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy, acceptability and unintended consequences of very low nicotine content cigarettes (VLNCC) in smokers with current or past year substance use disorders (SUD). The primary aim of this study is to determine whether 6 weeks of VLNCC compared to normal nicotine content cigarettes (NNCC) will result in more smoking cessation over 6 months and reduce cigarette use, cotinine, and biomarkers of toxicity. We will also assess the effects of VLNCC versus NNCC cigarettes on frequency of substance use and substance cravings (drugs and alcohol) because this is relevant to the safety of these products among smokers with SUD. Secondary aims are to study effects on cigarette craving, nicotine withdrawal and dependence, and depressed mood. Methods: Random assignment to VLNCC versus NNCC of up to 312 smokers with SUD will be balanced by gender, degree of tobacco dependence, and recent drug and alcohol use. All smokers will be provided with smoking counseling. Assessments over 6 months will assess effects both during the 6 weeks of using research cigarettes and after return to usual cigarettes. The importance is in determining the viability and safety of this public health strategy in terms of effects on both smoking and other substance use in a highly addicted population, which is essential to determine before the FDA implements this policy.

Detailed description: The 2009 passage of the Family Smoking Prevention and Tobacco Control Act (FSPTCA) gave the Food and Drug Administration (FDA) the authority to reduce levels of nicotine in cigarettes if appropriate for public health. This project addresses an area targeted for study by NIH and the FDA to assess the impact of products with reduced toxicity on tobacco use behaviors. Very-low nicotine content cigarettes (VLNCC) have been shown in some studies with smokers from the general population to reduce craving and withdrawal for tobacco relative to abstinence with little or no compensatory smoking, suggesting that a mandated reduction in the nicotine yield of cigarettes could substantially reduce smoking rates. This may be a particularly effective method of reducing smoking and smoking-related disease in special populations that have very high rates of tobacco dependence, such as people with substance use disorders (SUD). However, the consequences of this policy for smokers with SUD have not been investigated, and a call has gone out for studies of the safety of these products with vulnerable populations such as these. The purpose of this study is to determine the efficacy, acceptability and unintended consequences of VLNCC in smokers with SUD (current or past year) currently abstinent from hard drugs. The primary aims are to determine whether VLNCC will increase smoking cessation and reduce cigarette use, cotinine, and biomarkers of toxicity in smokers with SUD relative to baseline and to those randomized to a normal nicotine content cigarette (NNCC), and to determine any unintended effects of VLNCC on substance use and cravings to use substances so as to investigate safety. Secondary aims are to study effects on cigarette craving and nicotine withdrawal and dependence (mechanisms), and state depression (safety). A 2-group between-group by pre-post design will compare 6 weeks of VLNCC to NNCC; all smokers will also be provided with smoking counseling. Follow-up over 6 months will assess effects after return to usual cigarettes. The importance is in determining the viability and safety of this public health strategy in terms of effects on both smoking and other substance use in a highly addicted population, which is essential to determine before the FDA implements this policy.

Eligibility criteria: Inclusion Criteria::

* Diagnostic and Statistical Manual-5 criteria for current or past year substance use disorder
* smoke 10+ cigarettes/day for past 6 months
* zero breath alcohol, negative urine drug tests and a self-report of no drug use in the past 30 days on day of informed consent
* score of 4-8 on the Contemplation Ladder (individuals interested in quitting smoking someday and/or have thought about quitting)

Exclusion Criteria:

* active psychosis as evidenced by hallucinations or delusions
* actively quitting smoking or current use of any nicotine replacement or other smoking cessation treatment
* medication contraindications for smoking cessation (smoking cessation may change the bioavailability of antipsychotics, warfarin, theophylline and insulin)
* other medications that could affect smoking (naltrexone, buprenorphine, acamprosate, anti-seizure medications, disulfiram)
* if on psychotropic medications, not stabilized on psychotropic medications (i.e., anti-depressant, anti-anxiety or anti-manic medications changed within past 4 weeks)
* inability to understand informed consent in a test (true-false questions) on the key elements of the consent form

Primary outcomes:
measure: 7-day point-prevalence smoking abstinence
timeFrame: 6 weeks
Secondary outcomes:
measure: Total N'-nitrosonornicotine (NNAL)
timeFrame: 6 weeks
measure: Number of cigarettes smoked per day
timeFrame: 6 weeks
measure: Number of substance use days
timeFrame: 6 months
measure: Change in Beck Depression Inventory
timeFrame: Baseline and 6 weeks
measure: Total N'-nitrosonornicotine (NNN)
timeFrame: 6 weeks
measure: 3-hydroxypyrene (3-HOP)
timeFrame: 6 weeks
measure: 3-hydroxypropylmercapturic acid (3-HPMA)
timeFrame: 6 weeks
measure: Total urinary cotinine levels
timeFrame: 6 weeks
measure: duration of longest tobacco abstinence period
timeFrame: 6 weeks
measure: Questionnaire of Smoking Urges, Brief Form
timeFrame: 6 weeks
Other outcomes:
measure: Minnesota Nicotine Withdrawal Scale
timeFrame: 6 weeks
measure: Penn Alcohol Craving Scale
timeFrame: 6 weeks
measure: Drug Craving Questionnaire
timeFrame: 6 weeks
measure: Change in Contemplation Ladder
timeFrame: Baseline and 6 weeks
Locations:
city: Providence
country: United States
facility: Brown University's Center for Alcohol and Addiction Studies
state: Rhode Island
Study officials:
affiliation: Brown University
name: Damaris J Rohsenow, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Brown University
name: Rosemarie A Martin, PhD
role: STUDY_DIRECTOR
References: